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Abstract
Using immunohistochemistry, expression of p53, transforming growth factor-alpha (TGF-a), epidermal growth factor receptor
(EGFR), c-erbB-2/neu and proliferating cell nuclear antigen (PCNA) was examined in 26 fresh frozen tissue specimens of oro-
pharyngeal squamous cell carcinomas (SCCs). p53 gene mutations were examined by polymerase chain reaction (PCR)/DNA
sequencing methods in 22 carcinomas. The findings were examined for correlations with patients’ clinicopathological parameters.
Expressions of p53 and PCNA were also examined in 21 formalin-fixed corresponding tissues. Of the fresh frozen tissue specimens,
77% (20/26) showed expression and 68% (15/22) showed mutations (substitutions) of the p53, with significant clustering of the
mutations in exons 5 (8/22; 36%), 7 (4/22; 18%) and 8 (5/22; 23%). No mutations were found in exon 6. There was a discordance
between expression of p53 protein and mutations of the gene. Parallel to expression and mutations of the p53 found in most of the
specimens, expression of TGF-a, EGFR, c-erbB-2/neu and PCNA was found in 88% (22/25), 92% (23/25), 58% (14/24) and 91%
(21/23) of the specimens, respectively. For the formalin-fixed tissue specimens, 62% (13/21) and 90% (19/21) expressed p53 and
PCNA, respectively. Examining for correlations with patients’ clinicopathological parameters, expression of p53, TGF-a, EGFR
and c-erbB-2/neu seemed to negatively correlate with the increase of the tumour grade. The present work suggests that: (1) lack of
negative growth regulation due to inactivation of the p53 gene together with activation of other proto-oncogenes are necessary
genetic events in the carcinogenesis of oropharyngeal SCCs; (2) in oropharyngeal SCCs, p53 gene mutations were clustered in exons
5 (codons 130–186), 7 (codons 230–248) and 8 (codons 271–282) which perhaps suggests that tobacco carcinogens probably aect
the mutational hot spots of the p53 gene at codons 157, 175, 186, 248, 273 and 282; and (3) fresh frozen and formalin-fixed tissue
specimens give similar results when an immunohistochemical method is applied. The importance of p53, TGF-a, EGFR, c-erbB-2/
neu and PCNA as biomarkers in oropharyngeal SCCs deserves particular attention because it might oer further understanding of
the development of these carcinomas. # 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Worldwide, incidence of oral/pharyngeal squamous
cell carcinoma (SCC) is on the increase [1, 2]. In the
West, smoking of cigarettes and/or drinking of alcohol
have been etiologically associated with the development
of these carcinomas [1]. Carcinogenesis is a multi-step
process that involves a number of aberrant genetic
events. Among these, negative (tumour suppressor genes)
and positive (oncogenes) regulators of the transformed
state as well as growth factor pathway lesions have been
suggested [3]. Tumour suppressor genes and oncogenes
are thought to be susceptible to environmental carcino-
gens and mutagens [1, 3–5]. In carcinogenesis, activation
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of a single gene usually does not lead to immediate
transformation, but it is likely that multiple activations
and events are involved [1, 3–5].
Mutations of the p53 gene have been found in more
than 50% of diverse human tumour types [4]. These
mutations induce changes, probably conformational,
that prolong the half-life (6–24 h) of the p53 protein [4].
The resulting mutant protein accumulates within the
nuclei of malignant cells in amounts that can be detec-
ted by immunohistochemistry. p53 gene mutations have
been reported in about 40–50% of oral/pharyngeal
SCCs with codons 238–248 and 278–281 as probable
hotspots for these mutations [6, 7]. A number of studies
have examined association between expression and mu-
tation of the p53 and dierent tobacco- and/or alcohol-
related oral/pharyngeal SCCs [8–11]. p53 protein over-
expression has been found to positively correlate with
the patient’s history of heavy cigarette smoking and/or
alcohol drinking [8, 9], betel and tobacco chewing [10]
and snu dipping [11]. In patients with oral/pharyngeal
SCCs, however, there is a great heterogeneity in relating
the status of the p53 expression and mutation to clinical
and/or histopathological parameters of these patients
(reviewed in [5–7]). In fact, most of the published results
relating to this are conflicting. Studies on correlation
between p53 expression and tumour site, size, histo-
pathological grading and/or patients age and/or sex
have reported conflicting results (reviewed in [5–7]).
Both no correlations and positive correlations have
been reported (reviewed in [5–7]). Reports on the exact
role played by expression and mutation of the p53
found in oral/pharyngeal SCCs in relation to patients’
clinical and/or histopathological parameters were in-
conclusive [6, 7].
The transforming growth factor-alpha (TGF-a) is a
member of a growth factor family of which the epider-
mal growth factor (EGF) was the first to be described
[3, 12, 13]. Epithelial tumours often express the trans-
membrane glycoprotein receptor to TGF-a, namely the
epidermal growth factor receptor (EGFR, or c-erbB-1)
[3, 12, 13]. EGFR is a 170-kD transmembrane glyco-
protein with tyrosine-specific protein kinase activity
[3, 12, 13]. EGF and TGF-a interact with the target cell
through binding to the EGFR [3, 12, 13]. The c-erbB-2/
neu, mapped to human chromosome 17q21, encodes
a 185-kD transmembrane glycoprotein with tyrosine
kinase activity, and is closely related to the EGFR [3,
12, 13]. In vitro studies have suggested the existence of
an integrating erb receptor family network claiming
c-erbB-2/neu as the key molecule in receptor hetero-
dimerization [14].
Several studies have examined overexpression of
TGF-a, EGFR, c-erbB-2/neu in oral/pharyngeal SCCs
in relation to patients’ clinicopathological parameters,
and have reported contradictory results [15–25]. A study
of 91 cases of oral/pharyngeal SCCs has shown that
expressions of TGF-a and EGF appear to be among the
most important prognostic factors yet identified for
patients with these carcinomas [17]. Another study on
68 cases of laryngeal carcinoma has found that the sur-
vival rate in patients whose tumours expressed EGFR
and TGF-a was significantly lower compared to that
found in patients whose tumours were EGFR and
TGF-a negative [18]. On the contrary, a study of 43
cases of oral/pharyngeal SCCs has suggested that
increased production of TGF-a and EGFR in the car-
cinomas might serve as a marker for tumour progres-
sion [19]. However, simultaneous expression of TGF-a
and EGFR was only found in three tumours, which
harboured the highest levels of EGFR expression [19]. It
was then concluded that simultaneous expression of
TGF-a and EGFR indicate poor prognosis, prompting
the suggestion that increased production of these
growth factors in oral/pharyngeal SCCs might serve as
a target for therapy [19]. On the other hand, over-
expression of EGFR alone has also been suggested to be
of prognostic value for predicting either shorter disease-
free survival or shorter overall survival in oesopha-
geal carcinoma [20]. A significant positive association
between expression of c-erbB-2/neu and tumour pro-
gression in cases of oral SCCs has been reported [26].
Furthermore, it has also been suggested that over-
expression of the c-erbB-2/neu in oral SCCs was corre-
lated negatively with survival, thus indicating its
importance to serve as biomarker for poor prognosis
[27]. Other studies have reported that expression of
c-erbB-2/neu in oral/pharyngeal SCCs did not correlate
with patients’ survival [28, 29].
The proliferating cell nuclear antigen (PCNA) plays
an important role in nucleic acid metabolism, DNA
replication, DNA excision repair, chromatin assembly,
and in several instances it has been shown to be
involved in RNA transcription [30]. In immunohis-
tochemistry, expression of PCNA is used as a marker
to study the state of cell proliferation in normal and
neoplastic tissues [30].
Previously, it has been suggested that overexpression
of p53, TGF-a, EGFR and c-erbB-2/neu in oral/phar-
yngeal SCCs in relation to patients’ clinicopathological
parameters remained contradictory and controversial
[6, 7, 15–25]. There are also wide variations in the inci-
dence of biomarkers overexpression, intensity and
staining localisation. Thus, further studies are needed
on these biomarkers in oral/pharyngeal SCCs for uni-
formity and consistency. This might enhance our under-
standing of their role in regulation of cell proliferation
during carcinogenesis and tumour progression. To bet-
ter understand the relative importance of these bio-
markers in the development of oral/pharyngeal SCCs,
it was therefore the objective of the present work to:
(1) examine the expression and mutation (using PCR/
DNA sequencing methods) of p53, and the expression
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of TGF-a, EGFR, c-erbB-2/neu and PCNA using
avidin–biotin immunohistochemistry in fresh frozen tis-
sue specimens of oral/pharyngeal SCCs; (2) to examine
if there are correlations between expression of these
biomarkers and/or patients’ clinicopathological param-
eters, history of cigarette smoking and/or alcohol
drinking; and (3) compare results obtained by immuno-
histochemistry on expression of p53 and PCNA in fresh
frozen tissue with those in corresponding formalin-fixed
ones.
2. Materials and methods
2.1. Patients and tissue specimens
From the period September 1991 to November 1993,
surgical fresh biopsy tumour samples (approximately
0.5–1 cm3) were obtained from 26 consecutive patients
with previously untreated oral/pharyngeal SCCs oper-
ated on at the Department of Otolaryngology/Head &
Neck Surgery at the Haukeland University Hospital,
Bergen, Norway. There were 18 males and eight females
(age range 34–82 years, mean 65:6 2:5 SE, SD 12.83
years). The diagnosis of the tumours was based on clin-
ical examination and histopathological analysis of the
tissue specimens. All tumours were staged following
the 1987 UICC staging system. Accordingly, five tum-
ours were T1, seven tumours were T2 and 14 tumours
were T3 (Table 1). Regional lymph node involvement in
the neck was found in eight patients, while evidence for
distant metastasis was found in only one patient. Using
lesional tissue sections including also adjacent epithe-
lium from those selected for the current study, all the
cases had their histopathologic diagnosis confirmed by
one of the authors (A.C.J.) using cryostat sections of
all biopsies stained with haematoxylin and eosin (H&E),
at the Department of Odontology–Oral Pathology
and Forensic Odontology at the Haukeland University
Hospital, Bergen, Norway. The tumours were histolo-
gically graded as highly, moderately or poorly dier-
entiated according to Cawson and Eveson [31] (Table 1).
Tissue specimens were obtained at the time of biopsy or
primary surgery and were always taken from the inter-
face between the tumour and normal tissue using a knife
and a scalpel. The tumour tissue samples were bisected
(approximately 0.2–0.5 cm3). One-half was fresh frozen
in isopentane pre-chilled in liquid nitrogen and stored at
ÿ70C. The other half was used for diagnostic reporting
following fixation in 10% buered formalin, and rou-
tine processing. The samples consisted of SCCs from
oral (15 cases), laryngeal (seven cases) and pharyngeal
(four cases). The various subsites of oral carcinomas
included: gingiva (four cases), tongue (seven cases),
floor of the mouth (two cases) and hard palate (two
cases). Fresh punch biopsy specimens of normal oral
buccal mucosa were obtained from five volunteer sub-
jects. All the normal control biopsy specimens were
treated in the same way, as were the tumour specimens.
From the stored fresh frozen tissue samples, several
sections (6 mm thick) were prepared, mounted on glass
slides and stored at ÿ20C until use. Twenty-one cor-
responding formalin-fixed tissue carcinoma specimens
were available from the 26 frozen tissue specimens.
From these formalin-fixed tissues, several sections (6 mm
thick) were also prepared and stored until use. For the
26 patients, only data on anatomical site of the carci-
noma, histopathological diagnosis, clinical character-
istics, history of tobacco use and/or drinking of alcohol
were available (Table 1). Smoking was quantified by
number of cigarettes smoked per day, and accordingly
patients were grouped into non-smokers, light smokers
(1–10 cigarettes per day) moderate smokers (11–20
cigarettes per day) and heavy smokers (>20 cigarettes
per day) (Table 1). Data were also collected on cigar,
pipe and snu use. For alcohol drinking, patients were
grouped into non-drinkers, light drinkers (1–2 drinks
per day), moderate drinkers (3–5 drinks per day) and
heavy drinkers (>5 drinks per day) (Table 1).
2.2. Immunohistochemistry
The available numbers of the fresh frozen tissue sec-
tions investigated for each biomarker were not equal.
Two standard protocols previously described from our
laboratory were used. The avidin–biotin–peroxidase
complex (ABC) protocol used for fresh frozen tissue
immunohistochemistry and that used for formalin-fixed
tissue immunohistochemistry have been described in
detail elsewhere [32, 33]. The monoclonal antibodies
(MAbs) used, their sources, dilutions and incubation
times are summarised in Table 2.
As positive controls, fresh frozen tissue specimens of
papillary thyroid carcinomas (n=5) previously found
positive for TGF-a, EGFR and c-erbB-2/neu were in-
cluded. In addition, formalin-fixed, paran-embedded
carcinomas of the uterine cervix (n  5) previously
found positive for p53 and PCNA were included.
For each specimen (fresh frozen and formalin-fixed),
negative control incubations were performed where the
primary antibody was replaced with phosphate-buered
saline (PBS) and/or normal rabbit serum, normal mouse
serum of the same isotype and application of the ABC
substrate alone (to determine the quenching of endo-
genous peroxidase activity).
2.3. Evaluation of the immunohistochemistry
Whole-tissue sections (including epithelium adjacent
to the non-malignant lesional area, pre-malignant and
malignant areas when present in the specimen) were
examined with a light microscope at a final magnification
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of 400 for p53 and PCNA-positive nuclear staining.
For the TGF-a, EGFR and c-erbB-2/neu, the staining
was also assessed in the tissue sections at the same
magnification by determining its presence (membrane,
cytoplasmic and/or mixed membrane/cytoplasmic) or
absence. For all the biomarkers investigated, the stain-
ing was recorded as positive (+, >10% of the entire
tumour cells positive) and as negative (ÿ, <10% posi-
tive cells). The intensity of staining for all the bio-
markers examined was scored as: (a) weak, (b) moderate
and (c) intense staining.
2.4. DNA extraction
Of the 26 fresh frozen tissue carcinomas investigated,
specimens from 22 were available for total cellular
DNA extraction which was carried out using proteinase
K (Sigma, St. Louis, MO, USA) and phenol–chloro-
form, using a standard protocol as described in detail
elsewhere [34]. Purified DNA was quantified spectro-
photometrically using a spectrophotometer (Beckman,
Fullerton, CA, USA DU 530, Life Science).
2.5. Polymerase chain reaction (PCR)
Exons 5–9 of the p53 gene were amplified in
vitro from each tumour using primers described
earlier by Ryberg et al. [35]. The primer sequences and
PCR fragment sizes were as follows: exon 5 (299 bps):
50TTCAACTCTGTCTCCTTCCT30 (sense), 50GCAA-
TCAGTGAGGAATCAGA30 (antisense); exon 6 (224
bps): 50TGGTTGCCCAGGGTCCCCAG30 (sense), 50T-
GTGAGGGCCACTGACAACCA30 (antisense); exon 7
(218 bps): 50AGGCGCACTGGCCTCATCTT30 (sense),
50AGGGGTCAGCGGCAAGCAGA30 (antisense); ex-
ons 8/9 (445 bps): 50TTGGGAGTAGATGGAGCCT30
(sense), 50AGTGTTAGACTGGAAACTTT30 (anti-
sense). The primers were obtained from MedProbe,
Oslo, Norway. The PCR was carried out in the Gene-
Amp1 PCR System 9700 (PE Applied Biosystems, Foster
City, CA, USA). The 50-ml PCR-mixture reaction con-
sisted of 1 ml genomic DNA solution, 200 mM of each of
the four deoxynucleotide triphosphates (dNTPs), 0.25 U
of AmpliTaq1Gold DNA polymerase (5 U/ml, PE
Applied Biosystems, Foster City, CA, USA), 1.25 (for
primer exon 5), 1 (for primer exons 6 and 7) and 2.5 (for
primer exons 8/9) mMMgCl2, respectively, and 10 pmol
of each of the primers. A ‘hot start’ at 94C for 10 min
was followed by 40 cycles of amplification, where each
cycle consisted of 40 s denaturation at 94C, 1 min
annealing at 55C, and 1 min extension at 72C. The
last PCR cycle was followed by a final extension at 72C
for 7 min. Human placental DNA was used as normal
control. PCR reactions without DNA as a template
were included as negative controls. Determination of
the PCR amplification product was done by electro-
phoresis and staining with 0.5 mg/ml ethidium bromide
in a 1.5% agarose gel, and the amplified samples were
recorded. Before further analysis, PCR amplification
products were purified using either the QIAquick Gel
Extraction Kit or the QIAquick PCR Purification
Kit Protocols using a microcentrifuge as described in
QIAquick Spin Handbook (QIAGEN1, QIAquick2,
QIAvac).
2.6. DNA sequencing
After the initial PCR amplification analysis of all the
tumours, purified product of only the tumours that
showed amplification reaction with the PCR were sub-
jected to sequencing in a non-radioactive cyclic sequenc-
ing reaction carried out following the manufacturer’s
protocol described for the commercially available kit:
the ABI PRISM2 BigDye Cycle Sequencing Ready
Reaction Kit (PE Applied Biosystems, Foster City, CA,
USA). In this 10-ml PCR-mixture reaction, 2 ml from the
purified PCR products of the tumour, 4 ml from the
BigDye reaction mixture and 1.5 pmol from the sense or
antisense primers of the PCR used for exons 5, 7 and
8/9 as described above, were amplified. Sequencing was
done on the automated ABI PRISM2 377 DNA
Sequencer (PE Applied Biosystems, Foster City, CA,
USA). The software packages Vector NTI 5.1 and Align
X 1.0 (InforMax BioSuite2) version 5.0 for Windows2
(InforMax, Inc., North Bethesda, USA) were used to
analyse the results of sequencing.
Table 2
The primary monoclonal antibodies (MAbs) used, their dilutions, times of incubations and sources
Antigen Mouse MAb Dilutiona/times of incubation (min) at room temperature Source
p53 1801 1:1000/90/overnight Oncogene Science1, Mannhasset, USA
p53 DO-7 1:500/90/overnight DAKO1, Copenhagen, Denmark
p53 DO-1 1:1000/90 min/overnight Santa Cruz Biotechnology1, USA
TGF-a MAb Ab-2 1:50/60 Oncogene Science1, Mannhasset, USA
EGFR RPN.513 1:20/60 Amersham1, Bucks, UK
c-erbB2/c-neu Anti-(Ab-3)erbB-2 1:40/60 Oncogene Science1, Mannhasset, USA
PCNA PC10 1:1000/60/overnight Santa Cruz Biotechnology1, Santa Cruz, CA, USA
TGF-a, transforming growth factor-alpha; EGFR, epidermal growth factor receptor; PCNA, proliferating cell nuclear antigen.
a Diluted in phosphate-buered saline (PBS) containing 5% bovine serum albumin.
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2.7. Statistical analysis
Either Chi-square or two-tailed Fischer’s exact tests
(at p < 0:05 significance levels) were used to examine the
association between expression of biomarkers: p53,
TGF-a, EGFR, c-erbB-2/neu and the PCNA gene
products in the fresh frozen tissue samples of the oral/
pharyngeal SCCs, and the patients’ clinicopathological
parameters, history of cigarette smoking and drinking
of alcohol (separate and in combination).
3. Results
3.1. Immunohistochemistry
3.1.1. Expression of p53
A summary of the expression/intensity of staining
for the nuclear p53 (Fig. 1A) found in the fresh frozen
and formalin-fixed tissue carcinoma specimens is
shown in Table 1. Both fresh frozen and formalin-fixed
carcinomas showed expression of the p53 in the per-
iphery of the carcinoma cell nests located in its most
invasive regions, and in the dysplastic cells of the basal
region of the squamous epithelium. This finding was
most prominent in the highly dierentiated carcinomas,
but for the low dierentiated ones, heterogeneous in-
tense staining was found distributed throughout the
carcinoma cell nests. All the areas with cells that
showed expression of p53 in the formalin-fixed tissue
carcinomas were found comparable to those found in
the fresh frozen ones regarding location, intensity as
well as pattern of staining. The normal epithelium
located adjacent to the carcinomas in the fresh frozen
and formalin-fixed tissue carcinomas as well as the five
normal control oral mucosal epithelial specimens were
negative for p53.
3.1.2. Expression of TGF-
A summary of the expression/intensity for the cyto-
plasmic TGF-a (Fig. 1B) found in the fresh frozen tissue
carcinoma specimens is shown in Table 1. In 17 out of
the 22 carcinomas that showed expression of TGF-a,
additional weak staining for TGF-a was also seen in the
inflammatory cell infiltrate. The normal epithelium
located adjacent to the carcinomas as well as the five
normal control oral mucosal epithelial specimens
showed weak cytoplasmic staining in the basal/inter-
mediate cell layers of the epithelium. When found in the
normal epithelium, expression of TGF-a varied in all
the layers of the epithelium.
3.1.3. Expression of EGFR
A summary of the expression/intensity of staining for
the membrane EGFR (Fig. 1C) found in the fresh fro-
zen tissue carcinoma specimens is shown in Table 1. In
Fig. 1. Immunohistochemical detection of (A) p53, (B) TGF-a, (C) EGFR, (D) c-erbB-2/neu and (E) PCNA in a fresh frozen tissue specimen of
oropharyngeal squamous cell carcinoma (SCC) (250).
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nine out of the 23 carcinomas that showed expression of
EGFR, weak membrane staining was also found in the
basal/intermediate cell layers of the adjacent normal
epithelium. In the low and moderately dierentiated
carcinomas, more pronounced expression of EGFR
was found in nearly all the basal epithelial cell layers
and tumour tissues. With the increase of the tumour
grade, expression of the EGFR confined to the basal or
suprabasal cell layers of the epithelium. The five nor-
mal control oral mucosal epithelial specimens showed
weak membrane staining of EGFR in the basal/inter-
mediate cell layers of the epithelium.
3.1.4. Expression of c-erbB-2/neu
A summary of the expression/intensity of staining of
mixed membrane/cytoplasmic c-erbB-2/neu (Fig. 1D)
found in the fresh frozen tissue carcinoma specimens is
shown in Table 1. In all the carcinomas that showed
expression of c-erbB-2/neu, except for two cases, the
expression was found in the same areas of the carcino-
mas that showed expression of the EGFR. However,
the total cell areas of the carcinomas that showed
expression of the c-erbB-2/neu were smaller when
compared to those which showed expression of the
EGFR in the same carcinomas. The five normal
control oral mucosal epithelial specimens showed
weak mixed membrane/cytoplasmic staining of the
c-erbB-2/neu in the basal/intermediate cell layers of
the epithelium.
3.1.5. Expression of PCNA
A summary of the expression/intensity of staining of
nuclear PCNA (Fig. 1E) found in the fresh frozen and
formalin-fixed tissue carcinoma specimens is shown in
Table 1. Within each tumour, the intensity of PCNA
staining ranged from intense to weak. Both normal,
dysplastic and malignant epithelium in the fresh frozen
and formalin-fixed tissue specimens showed nuclear
staining of PCNA in large areas of the basal cell layers
of the epithelium. PCNA staining in the formalin-fixed
tissues followed the same pattern as that found in the
fresh frozen ones.
The possible correlations between expression of
the biomarkers investigated and tumour site, tumour
grade and patient’s history of cigarette smoking and/
or alcohol drinking in the fresh frozen tissue carci-
nomas was examined. The data (Table 3) showed no
statistically significant correlations to tumour site,
tumour grade, history of cigarette smoking and
drinking of alcohol alone, or combined history of
cigarette smoking and drinking of alcohol ( p > 0:05).
The expression of these biomarkers (except for the
Table 3
Proportions of the positive findings on the expression of p53, transforming growth factor-alpha (TGF-a), epidermal growth factor receptor (EGFR),
c-erbB-2/neu and proliferating cell nuclear antigen (PCNA) in the oropharyngeal squamous cell carcinomas (SCCs) according to tumour site and
grade, and patients’ history of cigarette smoking and/or alcohol drinking
p53 TGF-a EGFR c-erbB-2/neu PCNA
Tumour site
Oral (n  15) 12/15 (80%) 14/15 (93%) 9/15 (60%) 12/15 (80%) 12/15 (80%)
Larynx/pharynx (n  11) 8/11 (72%) 10/11 (91%) 5/9 (56%) 10/10 (100%) 9/11 (82%)
p  1:00 p  1:00 p  1:00 p  0:25 p  1:00
Tumour grade
I/II (n  12) 10/12 (83%) 10/11 (91%) 11/11 (100%) 6/10 (60%) 10/11 (91%)
III (n  14) 10/14 (71%) 12/14 (86%) 12/14 (86%) 8/14 (57%) 11/12 (92%)
p  0:65 p  1:00 p  0:49 p  1:00 p  1:00
Cigarette smoking
NS (n  8) 6/8 (75%) 7/8 (88%) 8/8 (100%) 5/8 (63%) 7/7 (100%)
LS/MS (n  6) 5/6 (83%) 6/6 (100%) 6/6 (100%) 2/5 (40%) 5/6 (83%)
HS (n  12) 9/12 (75%) 9/11 (82%) 9/11 (82%) 7/11 (64%) 9/10 (90%)
p  0:91 p  0:54 p  0:25 p  0:64 p  0:55
Alcohol drinking
ND (n  8) 7/8 (88%) 8/8 (100%) 8/8 (100%) 6/8 (75%) 6/6 (100%)
LD (n  5) 4/5 (80%) 4/4 (100%) 4/4 (100%) 3/4 (75%) 4/4 (100%)
MD/HD (n  5) 4/5 (80%) 5/5 (100%) 4/5 (80%) 1/4 (25%) 4/5 (80%)
p  0:91 – p  0:28 p  0:20 p  0:34
Cigarette smoking and alcohol drinking
NS and ND (n  6) 5/6 (83%) 6/6 (100%) 6/6 (100%) 4/6 (67%) 5/5 (100%)
LS and ND/MS and MD (n  4) 4/4 (100%) 4/4 (100%) 4/4 (100%) 1/3 (33%) 4/4 (100%)
HS and ND/HS and LD (n  6) 5/6 (83%) 5/5 (100%) 5/5 (100%) 4/5 (80%) 4/4 (100%)
HS and HD (n  2) 1/2 (50%) 2/2 (100%) 1/2 (50%) 1/2 (50%) 1/2 (50%)
p  0:49 – p  0:47 p  0:59 p  0:073
HS, heavy smoker; MS, moderate smoker; LS, light smoker; NS, non-smoker; HD, heavy drinker; MD, moderate drinker; LD, light drinker;
ND, non-drinker.
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PCNA) seemed to negatively correlate with the
tumour grade, but with no statistically significant
dierences ( p > 0:05).
3.2. DNA sequencing analysis
A summary of the substitution mutations (transi-
tions and transversions) of the p53 gene found in the
oral/pharyngeal SCCs investigated is shown in Table 4.
An example (in exon 5) of the sequencing results for
both (1) the normal placental DNA and (2) the tumour
DNA is illustrated in Fig. 2. Of the 22 carcinomas
investigated, 68% (15/22) showed mutations in exons 5
(8/22; 36%), 7 (4/22; 18%), 8 (5/22; 23%) and 9 (2/22;
9%) (Table 4). No mutations were found in exon 6.
The incidence of p53 mutations was found higher in
laryngeal tumours (5/6; 83%) compared to those of
pharyngeal (2/3; 67%) and/or oral ones (8/13; 62%).
However, the association was not statistically sig-
nificant ( p > 0:05). The incidence of p53 mutations
was found to be greater in higher grade (III) tumours
(8/15; 53%) compared to lower grade (I/II) tumours (7/
15; 47%), but this dierence was also not statistically
significant ( p > 0:05). There were 22 substitution
mutations found in the carcinomas investigated. These
22 mutations were distributed as 13 (59%) trans-
versions (three A!T in exons 7 and 9, two C!A in
exons 5 and 7, three T!G in exon 5, one A!C, one
C!G and one T!A in exon 5, two G!T in exons 5
and 8), nine (41%) transitions (three G!A in exons 7
and 8; four C!T in exons 5 and 8; two T!C in exons
5 and 7).
3.3. Relationship between p53 mutations and history of
cigarette smoking and/or alcohol drinking
In tumours from three patients (Tables 1 and 4) there
were three G:C!A:T mutations. In two of these three
patients (one heavy smoker/light drinker, one non-
smoker/non-drinker), these p53 gene mutations were
found at the CpG sites (248 and 273) (Tables 1 and 4).
In the third patient (heavy smoker/light drinker), p53
gene mutation was found at a non-CpG site (codon 271)
(Tables 1 and 4). In tumours from two other patients
(one moderate smoker/moderate drinker/snu dipper,
one heavy smoker/snu dipper), p53 gene mutations
were found at the CpG sites (157, 186, respectively).
There were also four C:G!T:A transitions in tumours
from four patients (one non-smoker, one heavy smoker/
light drinker, one moderate smoker/moderate drinker,
Table 4
Mutations of the p53 gene (exons 5, 7–9) found in the oropharyngeal squamous cell carcinomas (SCCs)
Tumour No. Exon 5 codon/
mutation
Exon 7 codon/
mutation
Exon 8 codon/
mutation
Exon 9 codon/
mutation
Expression and intensity
of staining for p53 protein
1 – – – – +, c
2 182/TGC!CGC – – – –
4 157/GTC!GTA – – – +, a
5 – – – – –
6 – 230/ACC!TCC 271/GAG!AAG – +, b
7 130/CTC!GTC – – – –
142/CCT/CTT
8 – 248/CGG!CGA (S) – – +, c
10 147/GTT!GTG (S) – 282/CGG!TGG – +, b
11 – – – – +, a
12 – – 271/GAG!TAAa – +, c
13 166/TCA!TCC – – – +, a
14 147/GTT!GTG (S) – 273/CGT!CAT – +, b
15 – 236/TAC!CAC – 312/ACC!TCC +, c
17 – – 282/CGG!TGG – +, c
18 – – – – –
19 – – – – +, a
20 – – – 320/AAG!TAGa –
21 174/AGG!AGT 247/AAC!AAA – – +, c
175/CGC!CGT
22 147/GTT!GTG (S) – – – +, c
186/GAT!GAA
23 – – – – +, a
25 – – – – +, a
26 – – – – +, a
Total % 36% (8/22) 18% (4/22) 23% (5/22) 9% (2/22) 77% (17/22)
All tumours from Table 1 (except tumours no. 3, 9, 16 and 24) were investigated for p53 gene mutations. (S), silent.
a Stop codon.
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one non-smoker/non-drinker). These transition muta-
tions were found at codon 142, and CpG sites 175 and
282, respectively (Tables 1 and 4). In only two patients
(one light smoker, one heavy smoker/light drinker), we
found two G:C!T:A transversions, one at codon 174
and other at codon 271 (Tables 1 and 4).
4. Discussion
The p53 tumour suppressor gene plays a fundamental
role in the development of human tumours. Many other
proto-oncogenes including the erbB family, are involved
in growth regulation, and when expressed wrongly,
generate growth signals that might prevail other cell-
ular controls. Immunohistochemical markers have been
found helpful in routine histopathological evaluation of
oral/pharyngeal SCCs. The present study was under-
taken to examine the expression of five immunohisto-
chemical markers (p53, TGF-a, EGFR, c-erbB-2/neu
and PCNA) in oral/pharyngeal SCCs. The hypothesis
was that oropharyngeal SCCs demonstrating lack of
negative growth regulation due to inactivation of p53
(stable protein and/or mutated gene), might also
demonstrate activation of some other proto-oncogenes
involved in the process of carcinogenesis. If this pre-
vails, it might lead to a better understanding of the
development of these carcinomas and may emerge as a
useful prognostic indicator. We found high and similar
levels of expression of p53 protein (77%; 62%) in both
fresh frozen and formalin-fixed tissues of the oral/
pharyngeal SCCs examined by anti-p53 MAbs 1801,
DO-7 and/or DO-1. There were no dierences in the
expression of p53 between fresh frozen and formalin-
fixed tissue specimens. These findings agree with other
studies on oral/pharyngeal SCCs [36, 37]. We also
found that immunolocalization of the p53 protein
staining was similar to that of the PCNA, indicating
that p53 protein expression was found increased in
areas with proliferative activity. This might indicate
involvement of the mutated form of the p53 protein in
the alteration of the cell cycle regulation process. In our
study, p53-positive immunoreaction was found in the
periphery of the tumour cell nests and in the dysplastic
cells of the basal region of the squamous epithelium.
Both of these are considered to be areas of active cell
division. This might support the suggestion of a corre-
lation between positive p53 staining and proliferative
activity of these cells as reported by others [38, 39].
There is a prolonged dispute as to whether p53
expression detected by immunohistochemistry harbours
a mutated event (reviewed in [6, 7]). PCR/DNA sequenc-
ing methods were used to analyse p53 gene mutations in
22 matched carcinomas (Table 4). For these carcinomas,
17 were positive for p53 expression with immunohisto-
chemistry and five were negative. However, mutations
Fig. 2. An example of polymerase chain reaction (PCR) sequence
analysis for a squamous cell carcinoma (SCC) and normal DNA in
exon 5. ABI PRISM2 electrophotograms of normal DNA (I) and
carcinoma DNA (II) are shown in 50–-30 (sense) directions. Multiple
alignments of the tumour mutation has shown T!A transversion
(Asp–Glu) in codon 186.
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in the p53 gene were found in only 11 out of the 17
carcinomas that showed expression of the p53 protein.
In the remaining five carcinomas which were negative
for p53 expression, three showed mutations in the p53
gene (Tables 1 and 4). These findings suggest that use of
immunohistochemistry can provide indication for pres-
ence of mutation to a reasonable degree. Thus, results
of p53 expression require further analysis by molecular
techniques. p53 gene mutations were detected in speci-
mens that appeared negative by immunohistochemistry
in our study. This might be related to presence of point
mutations leading to increased instability of the p53.
In human tumours, most of the p53 gene mutations
occur in the highly conserved regions (exons 5–9) of the
gene [6, 7, 40]. Epidemiological data from the West have
linked cigarette smoking and/or drinking of alcohol to
the development of oral/pharyngeal SCCs [1, 40]. Dif-
ferences in p53 expression and mutation found in oral/
pharyngeal SCCs with or without history of tobacco use
and/or drinking of alcohol have been reported [6, 7, 40].
In our study, some of the p53 gene mutations found
were associated with exposure to tobacco and alcohol.
In addition, locations of the changes within the p53
gene regarding the CpG and non-CpG sites were also
associated with exposure to tobacco and alcohol. In
tumours from some patients who neither smoked nor
drank, we also found mutations at the CpG sites, and
other mutations associated with cigarette smoking. The
total number of carcinomas investigated in the present
study (n  22) was relatively small compared to those
investigated by others [8, 9, 36, 37]. Nevertheless, our
findings support the suggestion that tobacco carcino-
gens probably aect the CpG sites in the mutational hot
spots of exons 5 (codons 157, 175, 186), 7 (codon 248)
and 8 (codons 273 and 282) of the p53 gene [6, 8, 9, 40].
These observations, however, must be regarded as pre-
liminary and need to be further clarified by examining
suciently large patient cohorts to determine the sig-
nificance of the p53 status and tobacco in carcinogenisis
of oral/pharyngeal SCCs. In this study, some of the
tumours showed multiple mutations in the p53 gene
(Table 4), which is in line with other studies [41, 42]. In
one of the tumours (No. 2), no p53 protein expression
or mutations were found in the tumour metastasis.
In this work, in all areas of malignancy as well as
the dysplastic basal epithelium that previously showed
expression of p53 and PCNA, expressions of TGF-a,
EGFR and c-erbB-2/neu were found. In contrast to
p53, EGFR and c-erbB-2/neu expressions, expression of
TGF-a was also found in the inflammatory infiltrate in
some of the carcinomas investigated. Increased expres-
sion of the TGF-a and EGFR reported in this study
agree with findings of others in tumours and cell lines
from patients with oral/pharyngeal SCCs [43, 44]. We
found simultaneous expression of TGF-a and EGFR in
21 out of the 25 carcinomas investigated, and even in the
adjacent normal epithelium. This finding also agrees
with others [15, 16], and it might also support the sug-
gestion of TGF-a–EGFR autocrine loop involvement in
the neoplastic progression of human tumours [15, 16, 45–
47]. Nevertheless, neither others [15, 16, 45–47], nor our
own research group could conclude on whether TGF-a
and EGFR have any fundamental role in the develop-
ment of oral/pharyngeal SCCs. It has been suggested
that EGFR can be activated by TGF-a only when the
growth factor receptor reaches a critical concentration,
conferring a clonal growth advantage of cells expressing
EGFR [48, 49]. This finding has also been suggested
to indicate that development of elevated TGF-a and
EGFR levels might signal an early event in carcino-
genesis [50].
In this study, expression of the c-erbB-2/neu was
found in the normal epithelium adjacent to the carcino-
mas as well as in the control oral epithelium. This
finding agrees with a previous report [28]. In breast
tumours, membrane staining of the c-erbB-2/neu has
been suggested to be associated with c-erbB-2/neu am-
plification [48]. Cytoplasmic staining of c-erbB-2/neu
has been reported [46, 49], but its interpretation has been
controversial. However, findings of mixed cytoplasmic/
membrane staining were suggested to identify the
c-erbB-2/neu [46]. In line with that, we found mixed
cytoplasmic/membrane staining in 14 out of the 24 car-
cinomas investigated, and the staining was blocked
using the specific blocking peptides. Thus, cytoplasmic
staining observed in our study might support the sug-
gestion of EGFR role in papillary thyroid carcinoma,
which has suggested incomplete degradation of the
c-erbB-2/neu receptor [47, 49]. The findings of high
cytoplasmic expression of TGF-a, membrane staining
of EGFR and mixed membrane/cytoplasmic staining
of c-erbB-2/neu in the present study agree with others
[15, 16, 28]. Such an observation was suggested to relate
either to ‘‘field cancerization’’ or ‘‘condemned mucosa’’
[50, 51]. In these two concepts, multiple foci of pre-
malignant or malignant changes may occur as a result
of exposure of the entire epithelium to initiating agents
like tobacco smoke and alcohol [50, 51]. In our study,
however, no correlations were found between ex-
pression of these biomarkers and patients’ clinico-
pathological parameters, perhaps due to the small
number of carcinomas examined.
In conclusion (1) lack of negative growth regulation
due to inactivation of the p53 gene, together with acti-
vation of other proto-oncogenes, are necessary genetic
events in the carcinogenesis of oral/pharyngeal SCCs,
(2) in oral/pharyngeal SCCs, p53 gene mutations were
clustered in exons 5 (codons 130–186), 7 (codons 230–
248) and 8 (codons 271–282) which might suggest that
tobacco carcinogens probably aect the mutational hot
spots of the p53 gene at codons 157, 175, 186, 248, 273
and 282, and (3) fresh frozen and formalin-fixed tissue
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specimens give similar results when an immunohisto-
chemical method is applied. The importance of p53,
TGF-a, EGFR, c-erbB-2/neu and PCNA as biomarkers
in oral/pharyngeal SCCs deserves particular attention.
This might oer further understanding of the develop-
ment of these carcinomas based on specific p53, TGF-a,
EGFR, c-erbB-2/neu and PCNA tumour targeting. In
oral/pharyngeal SCCs, however, the need for carefully
controlled studies comparing qualitative/quantitative
determinants of frequency and identity of oncogenes,
proto-oncogenes and/or tumour suppressor genes and
examination of suciently large patient cohorts to
determine potential prognostic significance is apparent.
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